Castle Rock Wealth Management LLC Sells 6,786 Shares of Danaher Co. (NYSE:DHR)

Castle Rock Wealth Management LLC decreased its holdings in Danaher Co. (NYSE:DHR - Free Report) by 86.0% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,105 shares of the conglomerate's stock after selling 6,786 shares during the period. Castle Rock Wealth Management LLC's holdings in Danaher were worth $224,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Heck Capital Advisors LLC purchased a new stake in Danaher during the 4th quarter worth approximately $27,000. Golden State Wealth Management LLC acquired a new position in shares of Danaher during the 4th quarter worth about $31,000. Strategic Financial Concepts LLC purchased a new position in Danaher during the 4th quarter worth approximately $31,000. Pineridge Advisors LLC grew its holdings in shares of Danaher by 63.3% during the fourth quarter. Pineridge Advisors LLC now owns 147 shares of the conglomerate's stock worth $34,000 after buying an additional 57 shares during the last quarter. Finally, Kentucky Trust Co acquired a new position in Danaher in the 4th quarter valued at $34,000. Hedge funds and other institutional investors own 79.05% of the company's stock.

Insider Activity

In other news, EVP Christopher Paul Riley sold 15,805 shares of the business's stock in a transaction dated Wednesday, April 30th. The shares were sold at an average price of $198.00, for a total value of $3,129,390.00. Following the completion of the sale, the executive vice president now owns 15,179 shares of the company's stock, valued at approximately $3,005,442. The trade was a 51.01% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Chairman Steven M. Rales sold 1,250,000 shares of Danaher stock in a transaction on Monday, May 12th. The shares were sold at an average price of $196.74, for a total value of $245,925,000.00. Following the completion of the transaction, the chairman now directly owns 3,105,808 shares of the company's stock, valued at $611,036,665.92. This represents a 28.70% decrease in their ownership of the stock. The disclosure for this sale can be found here. 11.10% of the stock is owned by insiders.

Danaher Price Performance

DHR traded up $0.21 during midday trading on Thursday, hitting $193.29. The company had a trading volume of 727,836 shares, compared to its average volume of 3,467,484. The firm's 50-day simple moving average is $191.68 and its 200-day simple moving average is $212.83. The company has a market capitalization of $138.33 billion, a PE ratio of 36.57, a P/E/G ratio of 2.66 and a beta of 0.80. Danaher Co. has a twelve month low of $171.00 and a twelve month high of $281.70. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.05 and a current ratio of 1.40.

Danaher (NYSE:DHR - Get Free Report) last announced its quarterly earnings results on Tuesday, April 22nd. The conglomerate reported $1.88 EPS for the quarter, beating analysts' consensus estimates of $1.62 by $0.26. Danaher had a return on equity of 10.82% and a net margin of 16.33%. The company had revenue of $5.74 billion during the quarter, compared to analysts' expectations of $5.58 billion. Equities research analysts predict that Danaher Co. will post 7.63 EPS for the current fiscal year.

Danaher Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, July 25th. Investors of record on Friday, June 27th will be issued a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a yield of 0.66%. Danaher's payout ratio is 24.85%.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on DHR shares. Guggenheim reaffirmed a "buy" rating and issued a $250.00 target price on shares of Danaher in a research note on Wednesday, April 23rd. Wall Street Zen upgraded Danaher from a "hold" rating to a "buy" rating in a research note on Sunday. Robert W. Baird lowered their price objective on shares of Danaher from $231.00 to $225.00 and set an "outperform" rating on the stock in a research note on Wednesday, April 23rd. JPMorgan Chase & Co. lowered their price objective on shares of Danaher from $280.00 to $260.00 and set an "overweight" rating on the stock in a research report on Tuesday, April 22nd. Finally, UBS Group reduced their target price on shares of Danaher from $275.00 to $240.00 and set a "buy" rating for the company in a research note on Wednesday, April 23rd. Four research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $263.24.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.